Ceribell to Participate in the 45th Annual TD Cowen Healthcare Conference
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnosis and management, has announced its participation in the 45th Annual TD Cowen Healthcare Conference. The company's CEO and Co-founder, Jane Chao, Ph.D., along with CFO Scott Blumberg, will engage in a fireside chat scheduled for March 3, 2025, at 6:50 AM PST / 9:50 AM EST.
Interested parties can access both live and archived versions of the presentation through the Investor Relations section of Ceribell's website at investors.ceribell.com.
Ceribell (Nasdaq: CBLL), una società di tecnologia medica specializzata nella diagnosi e gestione delle condizioni neurologiche, ha annunciato la sua partecipazione alla 45ª Conferenza Sanitaria Annuale TD Cowen. Il CEO e co-fondatore dell'azienda, Jane Chao, Ph.D., insieme al CFO Scott Blumberg, parteciperanno a una chiacchierata informale programmata per 3 marzo 2025, alle 6:50 AM PST / 9:50 AM EST.
Le parti interessate possono accedere sia alle versioni in diretta che a quelle archiviate della presentazione attraverso la sezione Relazioni con gli Investitori del sito web di Ceribell all'indirizzo investors.ceribell.com.
Ceribell (Nasdaq: CBLL), una empresa de tecnología médica especializada en el diagnóstico y manejo de condiciones neurológicas, ha anunciado su participación en la 45ª Conferencia Anual de Salud TD Cowen. La CEO y cofundadora de la compañía, Jane Chao, Ph.D., junto con el CFO Scott Blumberg, participarán en una charla informal programada para el 3 de marzo de 2025, a las 6:50 AM PST / 9:50 AM EST.
Las partes interesadas pueden acceder tanto a las versiones en vivo como a las archivadas de la presentación a través de la sección de Relaciones con Inversores del sitio web de Ceribell en investors.ceribell.com.
세리벨(Ceribell) (Nasdaq: CBLL)은 신경학적 질환 진단 및 관리에 특화된 의료 기술 회사로, 제45회 연례 TD Cowen 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO이자 공동 창립자인 제인 차오 박사와 CFO 스콧 블룸버그가 2025년 3월 3일 오전 6:50 PST / 오전 9:50 EST에 예정된 대화에 참여할 것입니다.
관심 있는 당사자들은 세리벨 웹사이트의 투자자 관계 섹션을 통해 발표의 실시간 및 아카이브 버전을 모두 이용할 수 있습니다: investors.ceribell.com.
Ceribell (Nasdaq: CBLL), une entreprise de technologie médicale spécialisée dans le diagnostic et la gestion des troubles neurologiques, a annoncé sa participation à la 45ème Conférence Annuelle TD Cowen sur la Santé. La PDG et co-fondatrice de l'entreprise, Jane Chao, Ph.D., ainsi que le CFO Scott Blumberg, participeront à une discussion informelle prévue pour le 3 mars 2025, à 6h50 PST / 9h50 EST.
Les parties intéressées peuvent accéder aux versions en direct et archivées de la présentation via la section Relations Investisseurs du site web de Ceribell à l'adresse suivante : investors.ceribell.com.
Ceribell (Nasdaq: CBLL), ein Medizintechnologieunternehmen, das sich auf die Diagnose und das Management neurologischer Erkrankungen spezialisiert hat, hat seine Teilnahme an der 45. jährlichen TD Cowen Gesundheitskonferenz bekannt gegeben. Die CEO und Mitbegründerin des Unternehmens, Jane Chao, Ph.D., wird zusammen mit CFO Scott Blumberg an einem Gespräch teilnehmen, das für 3. März 2025 um 6:50 Uhr PST / 9:50 Uhr EST geplant ist.
Interessierte Parteien können sowohl auf die Live- als auch auf die archivierten Versionen der Präsentation über den Bereich Investor Relations auf der Website von Ceribell unter investors.ceribell.com zugreifen.
- None.
- None.
SUNNYVALE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming 45th Annual TD Cowen Health Care Conference. The fireside chat will take place on Monday, March 3, 2025, at 6:50 a.m. Pacific Standard Time / 9:50 a.m. Eastern Standard Time.
Event: 45th Annual TD Cowen Health Care Conference
Date: Monday, March 3, 2025
Time: 6:50 a.m. PST / 9:50 a.m. EST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Corrie Rose
Press@ceribell.com
FAQ
When is Ceribell (CBLL) presenting at the TD Cowen Healthcare Conference 2025?
Who will represent Ceribell (CBLL) at the 2025 TD Cowen Healthcare Conference?
How can investors watch Ceribell's (CBLL) presentation at the TD Cowen Healthcare Conference?
What is the focus of Ceribell's (CBLL) medical technology business?
